1 option
CADTH reimbursement recommendation : indication: rheumatoid arthritis : recommendation : reimburse with conditions. Infliximab SC (Remsima SC) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Language:
- English
- Subjects (All):
- Antirheumatic agents.
- Physical Description:
- 1 online resource (8 pages)
- Edition:
- First edition.
- Place of Publication:
- Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2021.
- Summary:
- Clinical evidence suggests that Remsima (infliximab) SCshould be reimbursed to treat adults with moderately to severely active RA in a similar way to other infliximab products, only if the cost does not exceed the drug plan cost of the least expensive IV formulation of infliximab.
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.